Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial Investigating Decitabine in Combination With a JAK-Inhibitor as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated/Blast Phase Myeloproliferative Neoplasms

NCT04282187 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT04282187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04282187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial Investigating Decitabine in Combination With a JAK-Inhibitor as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated/Blast Phase Myeloproliferative Neoplasms
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Recruiting
Start date
March 24, 2020
Completion date
November 11, 2027
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, essential thrombocythemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, myeloproliferative neoplasm, myeloproliferative neoplasm, not otherwise specified, polycythemia vera, primary myelofibrosis, secondary myelofibrosis